
China cuts both ways. The share calling "innovation in China" their biggest concern doubled to 14%, jumping from sixth place to second. Yet 11% still call it their top reason for optimism. Full report, from 569 insiders, a quarter of whom are C-Suite: endpoints.news/biopharma-sen…













